Chikungunya, Dengue, and Zika in Immunocompromised Hosts

• Published in: Current infectious disease reports 2018-04, Vol.20 (4), p.5-5, Article 5
• Main Authors: Darrigo, Luiz Guilherme, de Sant’Anna Carvalho, Alexandre Machado, Machado, Clarisse Martins
• Format: Article
• Language: English
• Subjects: Infectious Diseases; Medicine; Medicine & Public Health; N Theodoropoulos and S Pergam; Section Editors; Topical Collection on Transplant and Oncology; Transplant and Oncology (M Ison; Transplant and Oncology (M Ison, N Theodoropoulos and S Pergam, Section Editors)
• ISSN: 1523-3847; 1534-3146
• DOI: 10.1007/s11908-018-0612-2

Purpose of Review Describe the characteristics of chikungunya, dengue, and Zika in transplant recipients and immunocompromised hosts. Recent Findings Stem cell/bone marrow grafts, organs, and blood transfusions can transmit CHIKV/DENV/ZIKV infections, which are clinically similar, resembling influenza-like illness. Laboratory confirmation is necessary. In the acute phase, RT-PCR is preferred. DENV and ZIKV serology may cross-react. Delayed engraftment and extended viruria is observed in ZIKV+/HSCT recipients, while longer viremia is observed in DENV+/HSCT patients. Arbovirus persistence in organ tissues is generally unknown. Vaccine development is in early stages for CHIKV/ZIKV. No data is available to recommend the licensed DENV vaccine in transplant recipients. Summary In endemic areas, the assessment of epidemiological risk is mandatory. Donor deferral for 120 days in suspected or confirmed ZIKV+ has been recommended, while CHIKV+ donors should wait 30 days. No deferral is recommended for DENV+ donors. CHIKV/DENV/ZIKV tests should be included in the differential of febrile neutropenia and other transplant syndromes. Reassessment of DENV serology is urgently needed. Prospective studies are necessary to determine the impact of CHIKV/DENV/ZIKV in this special population.